Lupus
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0077 Please find an interview with my dear colleague @edvital on the importance of achieving and sustaining B cell depletion for improved clinical response in #lupus #SLE @RheumNow
https://t.co/4rTtFWxSvs https://t.co/4esoFTsgzC
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0124 EULAR recommended target oral Pred =<5mg/d. Should the threshold of LLDAS be changed to LLDAS5? Multicentre study showed the protection gained from mortality, irreversible organ damage accrual and flare was no different btw the two targets @RheumNow #EULARBEST https://t.co/GbP25tTmX8
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0145 Can we reclassify people with ANA+ RMD to improve clinical outcomes & stratify for basket trials? Deep machine learning identified distinct classes of ANA-RMD with distinct phenotypes & predicted long-term outcomes better than the legacy diagnoses @RheumNow https://t.co/W2hmmj0v8Y
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus showed ~half patients who met clinical response did not improve their psychological wellbeing. Factors of discordant: ancestry, damage, SLEDAI-2K @RheumNow https://t.co/9cqcPripA2
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare @RheumNow https://t.co/8IIgPuZUrF
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive therapies inc biologics? Data from an inception cohort showed low complement & cSLEDAI=>9 were assoc w increased risk of intensive therapy need/Tx failure @RheumNow https://t.co/jmahjcqom3
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on information from Lupus100 & supplemented by scientific data and relevant guidelines. I have tried it and worked well. Please disseminate https://t.co/a1qXGZyRE6 https://t.co/LTQM6A8Zq3
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0206 In a cohort study, of pts with #lupus nephritis, 81% tapered IS ~32 mths post-renal response. Of this, 17% flared. Strategies for safe tapering: ensure CR is achieved, low SLEDAI-2K at 12mths, low SLEDAI-2K & on HCQ at the time of tapering initiation @RheumNow https://t.co/hAMAdsL7Jn
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 POS0152 How prevalent is severe refractory #lupus? Multicentre cohort in Asia defined this as SLEDAI-2K=>10 + on GC + immunosuppressant. One in 7 met this definition, assoc w high activity & low T2T achievement. Useful for sample size calc for clinical study @RheumNow https://t.co/bq4gxX7kjI
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 POS0191 Development and validation of plasma biomarkers to predict #lupus flare in the next 12 weeks. Quick turnover results. Need to focus on steps to bring these novel tools from bench to clinical practice @RheumNow https://t.co/64EppGI7bv
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0059 Propensity match scoring of 179 pts w #lupus nephritis in AURA & AURORA1 vs ALMS. Triple therapy (voclosporin + MMF2g/d + low dose GC) led to earlier, greater reduction in proteinuria, & improved safety profile vs dual (MMF3g/d or Cyclo + High dose GC) @RheumNow https://t.co/UdcuaRTtzC
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 OP0017 If one target isn’t enough, why not two! Open label Phase I showed a double-pronged approach, compound BCMA-CD19 CAR Tcells (cCAR) improved clinical response, autoabs elimination & minimal infection in severe refractory #lupus nephritis @RheumNow #EULARBEST https://t.co/6MPHZKxKTB
In the wake of the EULAR 2023 guidelines on the management of SLE, it is perhaps pertinent that the EULAR 2024 congress features three abstracts from a large integrated analysis from five international Phase 3 belimumab trials in adults with active SLE (BLISS-76, BLISS-52, North East Asia, EMBRACE and BLISS-SC). Participants were randomised to belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard
Poster Hall